Medicine and Oral Surgery Department, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), 4585-116 Gandra, Portugal.
UNIPRO, Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), 4585-116 Gandra, Portugal.
Biomolecules. 2022 Apr 19;12(5):606. doi: 10.3390/biom12050606.
Our aim was to evaluate the expression of biomarkers, CD44v6, CD147, EGFR, p53, p63, p73, p16, and podoplanin in oral leukoplakias (OL) and to assess their potential for prediction of malignant transformation (MT). We analyzed the expression of CD44v6, CD147, EGFR, p53, p63, p73, p16, and podoplanin by immunohistochemistry in 52 OL, comprised of 41 low-grade (LG) dysplasia and 11 high-grade (HG) cases. Twelve healthy normal tissues (NT) were also included. Univariate and multivariate analysis were performed to evaluate any association with MT. Variable expression among the studied markers was observed, with a significant increase of high expression from NT to LG and HG cases in CD44v6 (p = 0.002), P53 (p = 0.002), P73 (p = 0.043), and podoplanin (p < 0.001). In multivariate analysis, cases with high podoplanin score showed a significant increased risk of MT (HR of 10.148 (95% CI of 1.503−68.532; p = 0.017). Furthermore, podoplanin combined with binary dysplasia grade obtained a HR of 10.238 (95% CI of 2.06−50.889; p = 0.004). To conclude, CD44v6, p53, p73, and podoplanin showed an increasing expression along the natural history of oral carcinogenesis. Podoplanin expression independently or combined with dysplasia grade could be useful predictive markers of MT in OL.
我们的目的是评估生物标志物 CD44v6、CD147、EGFR、p53、p63、p73、p16 和 podoplanin 在口腔白斑（OL）中的表达，并评估它们预测恶性转化（MT）的潜力。我们通过免疫组织化学分析了 52 例 OL 中 CD44v6、CD147、EGFR、p53、p63、p73、p16 和 podoplanin 的表达，其中包括 41 例低级别（LG）异型增生和 11 例高级别（HG）病例。还纳入了 12 例健康正常组织（NT）。进行了单变量和多变量分析，以评估与 MT 的任何关联。在所研究的标志物中观察到可变表达，CD44v6（p = 0.002）、P53（p = 0.002）、P73（p = 0.043）和 podoplanin（p < 0.001）从 NT 到 LG 和 HG 病例的高表达显著增加。在多变量分析中，高 podoplanin 评分的病例 MT 风险显著增加（HR 为 10.148（95%CI 为 1.503-68.532；p = 0.017）。此外，podoplanin 结合二元异型增生分级获得的 HR 为 10.238（95%CI 为 2.06-50.889；p = 0.004）。总之，CD44v6、p53、p73 和 podoplanin 在口腔癌发生的自然史中表达逐渐增加。podoplanin 表达独立或与异型增生分级结合可作为 OL 中 MT 的有用预测标志物。
